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Study of Antirestenosis With the BiodivYsio
Dexamethasone-Eluting Stent (STRIDE):
A First-in-Human Multicenter Pilot Trial
Xiaoshun Liu,1 MD, Yanming Huang,1 MD, Claude Hanet,2 MD, Michel Vandormael,3 MD,
Victor Legrand,4 MD, Joseph Dens,1 MD, Jean Luc Vandenbossche,5 MD, Luc Missault,6 MD,
Christiaan Vrints,7 MD, and Ivan De Scheerder,1* MD, PhD
The aim of this multicenter pilot study was to evaluate the acute safety and efficacy of the
dexamethasone-eluting stent (0.5 g/mm2 of stent) implanted in patients with de novo
single-vessel disease. This study included 71 patients, 42% of whom had unstable angina
pectoris. An appropriately sized BiodivYsio Matrix Lo stent loaded with a total dexameth-
asone dose of 0.5 g/mm2 of stent was used. Technical device success rate was 95%.
Six-month MACE occurred in two patients (3.3%). Binary restenosis rate was 13.3%. Late
loss was 0.45. Late loss and percent diameter stenosis were lower in the unstable angina
pectoris patients compared to the stable patients (0.32  0.39 vs. 0.60  0.55 mm, P <
0.07, and 26.86  14 vs. 38.40  16%, P < 0.02). This study demonstrated the feasibility
and safety of the implantation of a dexamethasone-eluting stent and its effect on in-stent
neointimal hyperplasia. Catheter Cardiovasc Interv 2003;60:172–178.
© 2003 Wiley-Liss, Inc.
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INTRODUCTION
In-stent restenosis, mainly caused by an abundant neo-
intimal hyperplasia, remains the major limitation of cor-
onary stent implantation. Mural thrombi, inflammatory
response, smooth muscle cell (SMC) dedifferentiation,
migration, and proliferation, and extracellular matrix for-
mation all participate to the pathogenesis of neointimal
hyperplasia. Changing any of these factors might have an
impact on neointimal hyperplasia. Systemic delivery of
medications has been unsuccessful in reducing resteno-
sis. Local drug delivery via infusion devices introduced
additional complexity to the procedure and may not
deliver sufficient medication to the site of the injury. It
also resulted in insufficient results. Drug-eluting stents,
however, can deliver an adequate amount of medication
to the site of injury for a sufficient period of time and
have been proposed as an alternative approach to de-
crease neointimal hyperplasia. Some preliminary studies
have shown very promising results [1,2].
Dexamethasone is a generic anti-inflammatory com-
pound approved by the FDA over 30 years ago and is
widely used. Dexamethasone is a glucocorticoid, which
readily crosses cell membranes and binds to specific
cytoplasmic receptors, resulting in the modification of
protein synthesis, thereby inhibiting inflammatory re-
sponses. Continuous administration of hydrocortisone or
dexamethasone, either systemically or from periadventi-
tial polymers, has been shown to reduce reactive intimal
hyperplasia in rabbit and rat models of restenosis [3,4].
Local drug delivery of dexamethasone from a poly-L-
lactic acid-coated stent in a porcine model did not result
in a reduction of intimal hyperplasia [5]. However, it has
been shown that biodegradable polymers can cause in-
creased inflammation and neointimal thickening in a
porcine model [6].
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Preclinical studies, using the BiodivYsio drug delivery
phosphorylcholine stent, which has been shown to cause
no inflammatory reaction [7–10], loaded with a high dose
of dexamethasone have shown a decreased neointimal
hyperplasia [11] in a porcine coronary model.
The aim of this study was to evaluate the safety and
efficacy of the BiodivYsio Matrix Lo stent loaded with
dexamethasone. The primary objective was to evaluate
the proportion of patients having an angiographic reste-
nosis 6 months after receiving the BiodivYsio Matrix Lo
stent loaded with dexamethasone. The secondary objec-
tives were to evaluate the safety and the 6-month quan-
titative coronary angiographic endpoints after receiving
the BiodivYsio Matrix Lo stent loaded with dexametha-
sone.
MATERIALS AND METHODS
Dxamethasone-Loaded BiodivYsio Matrix Lo
Stent
The BiodivYsio Matrix Lo stent system consists of a
stainless steel stent coated with a phosphorylcholine (PC)
polymer. It has the ability to absorb and release thera-
peutic agents, providing an inert depot for controlled
local drug release [12]. Once loaded, the release of the
therapeutic agent from the coating takes place in a con-
trolled and sustained manner [13]. Therefore, when the
stent is placed in contact with the vessel wall, release of
the therapeutic agent is confined to the desired target
providing high local drug concentrations. Loading stud-
ies using dexamethasone have shown that after an im-
mersion time of approximately 5 min there is little or no
increase in the amount of drug absorbed onto the
BiodivYsio Matrix Lo stent. On contact with the sol-
vent, the PC coating swells, allowing the drug to be
absorbed into the coating [14]. This process occurs
immediately after the PC coating comes in contact
with the drug solution. The amount of drug absorbed
into the coating is dependent on the concentration of
the drug solution and the volume of coating on a stent.
Release of the absorbed therapeutic agents occurs by
passive diffusion out of the PC coating.
In vitro drug release studies using a 5 ml phosphate
buffer solution at 25°C have shown that formulated dexa-
methasone (molecular weight, 392.5; Gensia; 10 mg/ml
in isotonic solution) exhibited a fast in vitro release: 95%
of the drug was released in 25 min, and the total amount
of drug was released within 2 hr. A bulk-loaded dexa-
methasone (15 mg/ml in EtOH sparingly solution) was
released within 20 hr. The latter drug concentration and
11, 15, and 18 mm long BiodivYsio Matrix Lo stents
with a diameter of 3.0, 3.5, or 4.0 were used in this trial.
Patient Population
This multicenter prospective trial was performed at
eight interventional cardiovascular centers in Belgium.
Seventy symptomatic patients with documented myocar-
dial ischemia (stable or unstable angina pectoris, or pos-
itive exercise test) with de novo coronary lesions were
included in this study. All patients were required to agree
to a 6-month clinical and angiographic follow-up and had
to be over 21 years old. The reference vessel diameter of
the treated lesion was visually estimated to be  2.75
mm and  4.0 mm in diameter; target lesion stenosis
was 50% and 100%. Noncalcified lesions, 15 mm
long, requiring one appropriately sized 11, 15, or 18 mm
BiodivYsio Matrix Lo stent were included.
The following patient categories were excluded from
the study: patients with ostial and bifurcation lesions, left
ventricular ejection fraction  30%, recent acute myo-
cardial infarction (within 72 hr of the intended treat-
ment), history of cerebrovascular accident (CVA) or
transitory ischemic attack (TIA) in previous 3 months,
known hypersensitivity or contraindication to aspirin or
stainless steel, or a sensitivity to contrast dye, allergy to
heparin or ticlopidine, active peptic ulcer or upper gas-
trointestinal bleeding, renal failure, liver disease, or dia-
betes mellitus. The following patients who in the opinion
of the investigator could compromise the ability to par-
ticipate in this trial were also excluded: pregnant women
or those of child-bearing potential, those with a concur-
rent medical condition with a life expectancy of less than
12 months, or those under any medical or psychiatric
conditions.
The ethics committee at each center approved the
protocol. The consent form or modification based on
local independent ethics committee recommendations
was completed by all enrolled subjects and signed by the
operating physician.
Procedure
All patients were premedicated with acetyl salicylic
acid (ASA; 160 mg/d) orally. Oral ticlopidine 500 mg
was given before PTCA. Standard balloon angioplasty
was performed via the femoral approach. Heparin (100
U/kg) after insertion of the arterial sheath was weight-
adjusted and administered as needed to maintain an ac-
tivated clotting time (ACT) of approximately 250–300
sec. Intracoronary nitroglycerin 100–200 g was admin-
istered immediately prior to baseline angiography, post-
stent deployment, and after final postdilatation angiogra-
phy.
Initial angiograms were performed in two orthogonal
projections or, if not possible, in two different non-
orthogonal views perpendicular to the investigated arte-
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rial segment. Under the same angiographic conditions,
the same projections were repeated during the follow-up
studies.
After predilatation, angiography was performed and
evaluated. A premounted, appropriately sized BiodivYsio
Matrix Lo stent was selected and immersed in a solution of
15 mg/ml dexamethasone, yielding a total dexamethasone
dose of 0.5 g/mm2 of stent. The stent and delivery balloon
were allowed to rest in the sterile solution for a minimum of
5 min and then were left to air-dry in the sterile field for 5
min. After that time, the dexamethasone-loaded BiodivYsio
Matrix Lo stent was deployed at the treatment site. The
prepared stent delivery system was advanced over the
guidewire through the guiding catheter to the targeted lesion
site. The stent was positioned across the lesion and place-
ment was confirmed with fluoroscopic test injections.
After removal of the balloon catheter, contrast was
injected to assess the final angiographic result. In case of
a suboptimal stent apposition, additional high pressure or
upsized balloon inflations were performed.
Procedural success was defined as a 20% reduction in
diameter stenosis (DS) and less than 50% residual ste-
nosis stent implantation. After stent implantation, aspirin
was continued indefinitely and ticlopidine (250 mg/d)
was prescribed for 28 days in all cases.
Quantitative Coronary Angiographic Analysis
Preprocedural, post-PTCA, poststent, and 6-month fol-
low-up quantitative coronary angiographic measure-
ments were performed offline by a specially trained in-
vestigator who was not involved in the angioplasty
procedure. Quantitative coronary angiographic analysis
was performed using a computer-assisted automated ar-
terial contour detection system (AWOS version 4.01,
Siemens, Erlangen, Germany), which has been validated
in vitro and in vivo. Each lesion was analyzed in two
approximately orthogonal projections selected for maxi-
mally avoiding superimposition and vessel foreshorten-
ing. The distal end of the guiding catheter was used for
calibration in each analyzed projection. The in-lesion
segment was defined as the stent plus 5 mm proximal and
5 mm distal to the edge or the nearest side branch.
In-stent and in-lesion restenosis were defined as  50%
DS at follow-up, located within the stent and target
lesion, respectively. Reference and minimal luminal di-
ameter (MLD), as well as the degree of percentage di-
ameter stenosis before and after angioplasty, after stent
implantation, and at 6-month follow-up were studied. All
measurements were assessed in both obtained views and
averaged. Acute gain, late loss, and net gain were sub-
sequently calculated. Acute gain was defined as the dif-
ference between the post- and preprocedural MLD, while
late loss and net gain were calculated by subtracting the
MLD at follow-up from the postprocedural and prepro-
cedural MLD, respectively [15].
Clinical Follow-Up
All patients were asked to return to the investigative
site or their primary cardiologist for a clinical visit 4
weeks postprocedure to monitor acute clinical events. All
patients were contacted by telephone by the investigative
site at 3 months  1 week for a safety evaluation. All
subjects were required to return to the investigative site
for a repeat coronary angiography whether they were
experiencing symptoms or not. If a patient had a positive
exercise stress test at any time up to and including his
required follow-up, a repeat angiogram was performed.
Definitions, Study Endpoints, and Statistics
Intention-to-treat population was defined as all pa-
tients who received the dexamethasone-eluting stent.
Per-protocol population was defined as all patients in the
intention-to-treat population who did not deviate from
the protocol. The patients with unstable angina were
classified according to the Braunwald classification. Sta-
ble angina was defined according to the Canadian Car-
diovascular Society (CCS) classification. The unstable
group included patients with unstable angina (new onset
or changed pattern of angina over the previous 2 months)
and CCS class IV angina at presentation. The stable
group included patients with stable angina (CCS class I,
II, or III angina unchanged over  2 months) or patients
with a positive stress test. The primary endpoint was
angiographic restenosis. The secondary endpoints were
30-day and 6-month major adverse cardiac events (death,
myocardial infarction, or clinically driven target lesion
revascularization). Quantitative coronary angiographic
endpoints included late loss, loss index, and late MLD at
6-month control angiography.
Categorical variables were summarized using counts
and percentages. Continuous variables were summarized
using mean, standard deviation, minimum, maximum,
and median for variable not showing a normal distribu-
tion. For comparison of subgroups, the unpaired two-
tailed Student’s t-test was used. Results were considered
statistically significant at P  0.05.
RESULTS
From 16 January to 5 June 2001, 71 patients from
eight study sites were included. Table I represents the
baseline clinical characteristics of the study population.
The mean age was 61.9 with a range from 36 to 82 years.
Twenty-one percent were females. Sixty-eight percent of
the patients had hypercholesterolemia, 56% had hyper-
tension, 45% had a previous MI, 42% had unstable
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angina pectoris. Eleven patients were excluded from the
per-protocol analysis as they violated inclusion and/or
exclusion criteria. In three patients the target vessel ref-
erence diameter was  2.75 mm; two patients were
excluded because they were diabetic; in one patient the
study stent was used to treat a type F dissection after
balloon angioplasty; in one patient the study stent cov-
ered a  2 mm side branch; two patient were excluded
because of recent myocardial infarction; one patient with
triple-vessel disease was excluded because of planned
staged procedure; and finally one patient was excluded
because the target lesion was longer than 15 mm.
In-Hospital Results, 30-Day and 6-Month Major
Adverse Coronary Events
Technical device success (defined as study stent suc-
cessfully implanted as first stent) was achieved in 95% of
patients; there were no procedural MACE recorded. One
patient in whom the balloon angioplasty was complicated
by a long ( 30 mm) type F dissection, treated with a
single study stent, died during the hospital stay due to a
cardiac arrest following attempts to cannulate a central
vein. All other patients were discharged without compli-
cations 24 hr after stent implantation. During the 30-day
follow-up, one patient developed a non-Q-wave myocar-
dial infarction. Control coronarogram revealed a subtotal
occlusion of a covered  2 mm side branch. At 6-month
follow-up, two patients presented with recurrence of
symptoms. Both showed a significant restenosis in the
study stent, treated with balloon angioplasty. Table II
shows the 6-month MACE in the intention-to-treat pop-
ulation and the per-protocol population.
Angiographic Results
The angiographic characteristics of the intention-to-
treat stented coronary segments are presented in Table
III. Forty-seven percent of the patients had at least two-
vessel disease; 33% had lesion type B2 or C. Thirty-three
percent of stents were placed in right coronary artery,
39% in the left anterior descending artery (LAD), 20% in
the circumflex coronary artery. Quantitative coronary
analyses of the intention-to-treat population and per-
protocol population are summarized in Tables IV and V,
respectively. In the intention-to-treat population, the
mean lesion length was 9.91 mm with a range from 3 to
23.5 mm. The mean reference diameter at baseline was
2.95  0.52 mm. Minimal luminal diameter and percent
diameter stenosis before the procedure were 1.02  0.35
mm and 64.75%  11.81%, respectively. Late loss were
0.47 in lesion and 0.57 in the stent segment. Loss indexes




Mean age (years) 61.9 (range, 36/82)
Family history CHD 24 (34)
Hypercholesterolaemia 48 (68)
Hypertension 40 (56)
Peripheral vascular disease 5 (7)
Previous stroke 5 (7)
Previous MI 32 (45)
Previous PTCA 11 (15)
Never smoked 16 (23)
Current smokers 24 (34)
Ex-smokers 25 (25)
Not known 6 (8)
Stable angina 27 (38)
Unstable angina 30 (42)
Silent ischemia 14 (20)
CHD, coronary heart disease.
*Values are mean  SD or n (%).






Cardiac death 1 (1.4) 0
Q-wave MI 0 0
Non-Q-wave MI 1 (1.4) 0
TLR 2 (2.8) 2 (3.3)
CABG 0 0
Total MACE 4 (5.6) 2 (3.3)
*MI, myocardial infarction; MACE, major adverse cardiac events; TLR,
target lesion revascularazation; CABG, coronary artery bypass graft sur-
gery.
TABLE III. Angiographic Characteristics*
n (%)
Disease state
Single-vessel disease 38 (54)
Two-vessel disease 21 (30)
Three-vessel disease 10 (14)





First obtuse marginal 4 (6)






Lesion length (mm) 9.3 (range, 3–15)
*Values are mean  SD or n (%). LAD, left anterior descending artery;
RCA, right coronary artery; LCx, left circumflex artery.
aAccording to AHA/ACC classification.
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of in-lesion and in-stent segments were 0.34 and 0.36,
respectively.
In the per-protocol population, the mean lesion length
was 9.5 mm with a range from 3 to 15 mm. The mean
reference diameter at baseline was 2.95  0.54 mm.
Minimal luminal diameter and percent diameter stenosis
before the procedure were 1.02  0.37 mm and 64.95%
 12.14%, respectively. Late loss was 0.45. Loss index
was 0.32. Binary restenosis rate was 13.3%.
Angiographic Results in Stable and Unstable
Patients
Subset QCA analyses of stable vs. unstable patients
are shown in Table VI. At 6-month follow-up, the diam-
eter stenosis of stable vs. unstable patients was 38.40%
16% and 26.86%  14% (P  0.05), respectively. The
late loss was 0.60  0.55 vs. 0.32  0.39 mm (P 
0.03), respectively.
DISCUSSION
This multicenter phase 2 trial shows that it is feasible
to load a BiodivYsio Matrix Lo stent with dexametha-
sone and to deliver the stent safely at the target lesion
site. Particularly with the dexamethasone solution that
we used, the MACE rates at 6-month follow-up were
acceptable and comparable with the data recently pre-
sented for RAVEL (MACE, 5.8% [16]) and ELUTES
(MACE, 11% [17]); also, the late loss compared favor-
ably to the findings of other studies evaluating bare
noncoated [18,19], heparin-coated [20], and PC-coated
BiodivYsio coronary stents [21]. This suggests that local
delivery of dexamethasone by means of the BiodivYsio
Matrix Lo stent may have a significant inhibitory effect
on neointimal hyperplasia. This effect was more pro-
nounced in the patient subgroup with unstable angina
pectoris (Fig. 1). Unstable coronary plaques are known to
contain important amounts of inflammatory cells, con-
tributing to the vulnerability of the atherosclerotic
plaque, causing significant morbidity. The binary reste-
TABLE IV. STRIDE QCA Data Safety Set (n  71)*
In-lesion In-stent
Pre-RVD (mm) 2.95 0.52
Pre-MLD (mm) 1.03 0.35
Pre-% DS 64.75  1.81
Lesion length 9.91 (3–23.5)
Post-RVD (mm) 2.93 0.52 2.99  0.42
Post-MLD (mm) 2.47 0.46 2.67  0.42
Post-% DS 15.47  7.17 10.46  5.50
Follow-up RVD (mm) 2.91 0.49 2.87  0.51
Follow-up MLD (mm) 1.98 0.60 2.09  0.60
Follow-up % DS 32.30  14.80 27.11  15.10
Acute gain (mm) 1.45  0.52 1.64  0.48
Late loss (mm) 0.47  0.47 0.57  0.48
Loss index 0.34  0.36 0.36  0.31
*RVD, reference vessel diameter; MLD, minimal luminal diameter; DS,
diameter stenosis. n  64 for the follow-up parameters.
TABLE V. STRIDE QCA Data Per-Protocol Set*
Pre Post 6 Months
RVD (mm) 2.95 2.93 2.93
MLD (mm) 1.02 2.49 2.02
% DS 65 15 32
Acute gain (mm) 1.47
Late loss (mm) 0.45
Loss index 0.32
Binary restenosis rate (%) 13.3
*RVD, reference vessel diameter; MLD, minimal luminal diameter; DS,
diameter stenosis.
TABLE VI. STRIDE QCA Data of Stable Angina
vs. Unstable Angina*
Stable angina Unstable angina P
Pre-RVD (mm) 2.81  0.49 2.90  0.45 NS
Follow-up RVD (mm) 2.87  0.52 2.92  0.47 NS
Pre-MLD (mm) 1.06  0.28 1.01  0.31 NS
Follow-up MLD (mm) 1.80  0.70 2.14  0.51 NS
Pre-% DS 61.64  11 64.96  11 NS
Follow-up 38.40  16 26.86  14 0.017
Acute gain (mm) 1.33  0.51 1.45  0.52 NS
Late loss (mm) 0.60  0.55 0.32  0.39 NS (0.067)
Loss index 0.46  0.37 0.22  0.34 NS
*RVD, reference vessel diameter; MLD, minimal luminal diameter; DS,
diameter stenosis.
Fig. 1. Comparison of the % diameter stenosis between the
stable and unstable angina pectoris patient group. The unstable
group included patients with unstable angina (new onset or
changed pattern of angina over the previous 2 months and CCS
class IV angina at presentation). The stable group included
patients with stable angina (CCS class I, II, or III angina un-
changed over ≥ 2 months) or patients with a positive stress
test.
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nosis rate (13.3%) in this study was higher, however,
than in recent presented studies with drug-eluting stents
[1,2]. This might be due to the low dose of dexametha-
sone chosen in this study or because dexamethasone is
less powerful in inhibiting neointimal hyperplasia com-
pared to rapamycin or paclitaxel. Further studies using a
higher dose of dexamethasone are under way to optimize
this treatment modality.
Study Limitations
This study was an unblinded, nonrandomized pilot
study without a control group. It was performed in a
small selected group of patients. A randomized dose
finding trial is mandatory to confirm these results and to
evaluate the optimal dose needed to optimize these re-
sults.
CONCLUSIONS
Implantation of a dexamethasone-loaded BiodivYsio
Matrix Lo stent to treat de novo coronary lesions is
feasible and safe. There was no increased incidence of
subacute or late stent thrombosis, although no prolonged
antiaggregation treatment was given in this study. Clin-
ical event rate and clinically driven revascularization
need were low. Late loss was significantly lower com-
pared with similar studies with bare, heparin-coated and
PC-coated stents and the very low rate in unstable pa-
tients is interesting. Confirmation of an improved out-
come should be shown in a prospective randomized trial
comparing the dexamethasone-loaded stent with a non-
loaded stent.
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APPENDIX
Participating centers and investigators are CG St. Jean
Brussel (M. Vandormael), AZ St. Jan Brugge (L. Mis-
sault), UZ Antwerp (C. Vrints), UZ Ghent (Y. Taey-
mans), UCL St. Luc (C. Hanet), CHU Sart Tilman (V.
Legrand), CHU St. Pierre (J.L. Vandenbossche), and UZ
Leuven (I. De Scheerder).
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